AP Logo

Menu

SECTIONS

Iran war Russia-Ukraine war Español China Asia Pacific Latin America Europe Africa

TOP STORIES

Newsletters

The Morning Wire\ \ Our flagship newsletter breaks down the biggest headlines of the day. The Afternoon Wire\ \ Get caught up on what you may have missed throughout the day.

See All Newsletters

SECTIONS

Immigration Weather Education Transportation Abortion LGBTQ+ Notable Deaths America at 250

TOP STORIES

Newsletters

The Morning Wire\ \ Our flagship newsletter breaks down the biggest headlines of the day.

See All Newsletters

AP QUIZZES

Test Your News I.Q. — take our weekly quiz

SECTIONS

2026 Elections Election Results Election calendar White House Congress Supreme Court The latest AP-NORC polls

TOP STORIES

Newsletters

Ground Game\ \ Your guide to the biggest stories in politics, policy and U.S. elections.

See All Newsletters

SECTIONS

FIFA World Cup NFL MLB WNBA Tennis NBA Golf NHL

TOP STORIES

Newsletters

The Sports Wire\ \ Your home base for in-depth reporting from the world of sports.

See All Newsletters

SECTIONS

Movies Fashion Television Celebrity Interviews Music Books

TOP STORIES

Newsletters

AP Entertainment Wire\ \ Get AP's first personalized newsletter delivering you entertainment news twice a week.

See All Newsletters

SECTIONS

Tariffs Inflation Financial Markets Financial Wellness Technology

TOP STORIES

SECTIONS

Space Animals The Ancient World Climate Medicine

TOP STORIES

TOP STORIES

SECTIONS

Trending Better health At home Working well For the climate Eating well

TOP STORIES

SECTIONS

Photo Essays

TOP STORIES

Newsletters

The World in Pictures\ \ Get special access to AP's most compelling images from our global team of photojournalists.

See All Newsletters

SECTIONS

Indigenous peoples and climate Climate Questions Climate Migration India Focus

TOP STORIES

TOP STORIES

SECTIONS

Artificial Intelligence Social Media

TOP STORIES

SECTIONS

Food & Recipes Gardening Fashion Homes Travel Pets

TOP STORIES

TOP STORIES

Newsletters

World of Faith\ \ Comprehensive global coverage of how religion shapes our world.

See All Newsletters

SECTIONS

Política de EEUU Deportes Mundial de Fútbol FIFA

TOP STORIES

MORE

Sign in

Search Query Submit Search

Show Search Menu

Submit Search

AP Logo

Menu

SECTIONS

Iran war Russia-Ukraine war Español China Asia Pacific Latin America Europe Africa

TOP STORIES

Newsletters

The Morning Wire\ \ Our flagship newsletter breaks down the biggest headlines of the day. The Afternoon Wire\ \ Get caught up on what you may have missed throughout the day.

See All Newsletters

SECTIONS

Immigration Weather Education Transportation Abortion LGBTQ+ Notable Deaths America at 250

TOP STORIES

Newsletters

The Morning Wire\ \ Our flagship newsletter breaks down the biggest headlines of the day.

See All Newsletters

AP QUIZZES

Test Your News I.Q. — take our weekly quiz

SECTIONS

2026 Elections Election Results Election calendar White House Congress Supreme Court The latest AP-NORC polls

TOP STORIES

Newsletters

Ground Game\ \ Your guide to the biggest stories in politics, policy and U.S. elections.

See All Newsletters

SECTIONS

FIFA World Cup NFL MLB WNBA Tennis NBA Golf NHL

TOP STORIES

Newsletters

The Sports Wire\ \ Your home base for in-depth reporting from the world of sports.

See All Newsletters

SECTIONS

Movies Fashion Television Celebrity Interviews Music Books

TOP STORIES

Newsletters

AP Entertainment Wire\ \ Get AP's first personalized newsletter delivering you entertainment news twice a week.

See All Newsletters

SECTIONS

Tariffs Inflation Financial Markets Financial Wellness Technology

TOP STORIES

SECTIONS

Space Animals The Ancient World Climate Medicine

TOP STORIES

TOP STORIES

SECTIONS

Trending Better health At home Working well For the climate Eating well

TOP STORIES

SECTIONS

Photo Essays

TOP STORIES

Newsletters

The World in Pictures\ \ Get special access to AP's most compelling images from our global team of photojournalists.

See All Newsletters

SECTIONS

Indigenous peoples and climate Climate Questions Climate Migration India Focus

TOP STORIES

TOP STORIES

SECTIONS

Artificial Intelligence Social Media

TOP STORIES

SECTIONS

Food & Recipes Gardening Fashion Homes Travel Pets

TOP STORIES

TOP STORIES

Newsletters

World of Faith\ \ Comprehensive global coverage of how religion shapes our world.

See All Newsletters

SECTIONS

Política de EEUU Deportes Mundial de Fútbol FIFA

TOP STORIES

MORE

Sign in

Search Query Submit Search

Show Search Menu

Submit Search

Health

FDA approves a first-of-its-kind pill to cut cholesterol in high-risk patients

The logo for Merck appears above a trading post on the floor of the New York Stock Exchange, May 1, 2025. (AP Photo/Richard Drew, File)

The logo for Merck appears above a trading post on the floor of the New York Stock Exchange, May 1, 2025. (AP Photo/Richard Drew, File)

By MATTHEW PERRONE

Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year]

Add AP News on Google Add AP News as your preferred source to see more of our stories on Google. Share

Comments

Share

Link copied

WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-its-kind pill that can drastically reduce cholesterol in a way that’s previously only been available with expensive, injectable drugs.

The drug from Merck was OK’d on Thursday for patients with artery-clogging cholesterol that persists even after taking statins, the standard medications for cutting heart attack risk. Merck will market its pill under the brand name Lipfendra.

It’s the first noninjectable medication that works by blocking a liver protein called PCSK9. That protein limits the body’s ability to clear cholesterol from the blood, and biotech injectables targeting it have been available from Amgen and other drugmakers for more than a decade. But patient access has been stymied for years by high prices, insurance restrictions and limited prescribing by doctors.

Statins block some of the liver’s production of cholesterol and are the cornerstone of treatment. But even at the highest doses, many people need additional help lowering their LDL, or bad, cholesterol enough to meet medical guidelines.

Merck, which has headquarters in Rahway, New Jersey, won approval based on two studies in high-risk patients who added the company’s pill to their standard treatment, including statins. In one study of 3,000 patients, those taking Lipfendra saw their levels of LDL cholesterol drop more than 55% after six months. In a second study, patients averaged a reduction of 59% compared with patients who received a dummy pill.

That benefit dropped only slightly over a year, and side effects — including dizziness and diarrhea — were similar between those taking the pill or a placebo, researchers found. One caveat: The pill must be taken on an empty stomach.

Related Stories

A vial of testosterone cypionate in Columbus, Ohio, on Jan. 18, 2024. (AP Photo/Carolyn Kaster, File)

Trump officials want to make testosterone drugs easier to prescribe. Is that a good idea?

5 MIN READ

67

Erica Schwartz testifies during a Senate Health Education Labor and Pensions committee confirmation hearing to be the director of the Centers for Disease Control and Prevention on Capitol Hill, Wednesday, July 15, 2026, in Washington. (AP Photo/Mariam Zuhaib)

CDC nominee says she won’t betray science — while declining to challenge Kennedy’s actions

6 MIN READ

37

The French National Assembly is draped with the artwork "Marianne rêve" ("Marianne Dreams") by French street artist Seth, depicting Marianne the symbol of the French Republic, before lawmakers vote later on final approval of a bill allowing adults with incurable illnesses to receive lethal medication, in Paris, Wednesday, July 15, 2026. (AP Photo/Michel Euler)

France’s National Assembly gives final approval to assisted-dying bill after years of debate

5 MIN READ

30

The FDA reviewed the drug under its program that promises ultra-fast reviews for promising medications that serve the public interest. The pathway was created by then-FDA chief Dr. Marty Makary, who resigned from the agency in May after months of pressure from drugmakers, patients and other outside groups.

Read More

Heart disease is the nation’s leading cause of death, and high LDL cholesterol, which causes plaque to build up in arteries, is a top risk factor for heart attacks and strokes. While an LDL level of 100 is considered fine for healthy people, doctors recommend lowering it to at least 70 once people develop high cholesterol or heart disease — and even lower for those at very high risk.

\\\_

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

MATTHEW PERRONE

Perrone covers the intersection of medicine, business and health policy. He is based in Washington.

twitter mailto

Read Original at AP News